Cedar Wealth Management LLC Invests $371,000 in Hims & Hers Health, Inc. $HIMS

Cedar Wealth Management LLC purchased a new stake in Hims & Hers Health, Inc. (NYSE:HIMS) during the 2nd quarter, Holdings Channel.com reports. The fund purchased 7,446 shares of the company’s stock, valued at approximately $371,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Allworth Financial LP lifted its holdings in Hims & Hers Health by 20.0% during the 1st quarter. Allworth Financial LP now owns 2,006 shares of the company’s stock valued at $56,000 after purchasing an additional 334 shares during the last quarter. Alps Advisors Inc. acquired a new position in Hims & Hers Health in the first quarter valued at approximately $306,000. Cerity Partners LLC acquired a new position in shares of Hims & Hers Health in the 1st quarter valued at $325,000. Mutual of America Capital Management LLC boosted its holdings in Hims & Hers Health by 239.8% during the first quarter. Mutual of America Capital Management LLC now owns 98,402 shares of the company’s stock worth $2,908,000 after buying an additional 69,441 shares during the last quarter. Finally, CWM LLC boosted its stake in Hims & Hers Health by 38.0% during the 1st quarter. CWM LLC now owns 9,556 shares of the company’s stock worth $282,000 after acquiring an additional 2,633 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Insider Transactions at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 145,000 shares of the stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $55.35, for a total value of $8,025,750.00. Following the completion of the transaction, the chief financial officer owned 128,984 shares of the company’s stock, valued at $7,139,264.40. This represents a 52.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Andrew Dudum sold 128,127 shares of the stock in a transaction on Monday, August 18th. The shares were sold at an average price of $45.06, for a total value of $5,773,402.62. Following the completion of the transaction, the chief executive officer owned 89,521 shares of the company’s stock, valued at $4,033,816.26. The trade was a 58.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 712,336 shares of company stock valued at $37,611,319. Corporate insiders own 13.71% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on HIMS shares. Zacks Research lowered Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 19th. KeyCorp initiated coverage on shares of Hims & Hers Health in a report on Tuesday, October 21st. They set a “sector weight” rating for the company. Wall Street Zen downgraded Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. UBS Group set a $32.00 price objective on shares of Hims & Hers Health in a research report on Tuesday, November 4th. Finally, BTIG Research reissued a “buy” rating and set a $85.00 target price on shares of Hims & Hers Health in a report on Tuesday, November 4th. Two research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Hims & Hers Health presently has an average rating of “Reduce” and an average price target of $45.27.

Hims & Hers Health Price Performance

Hims & Hers Health stock opened at $37.09 on Friday. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.88 and a quick ratio of 1.64. Hims & Hers Health, Inc. has a one year low of $19.15 and a one year high of $72.98. The firm has a market cap of $8.44 billion, a PE ratio of 68.68, a price-to-earnings-growth ratio of 7.18 and a beta of 2.20. The stock’s fifty day moving average price is $50.63 and its two-hundred day moving average price is $51.22.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, November 3rd. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.03). The firm had revenue of $598.98 million for the quarter, compared to the consensus estimate of $578.99 million. Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The company’s revenue for the quarter was up 49.2% compared to the same quarter last year. During the same period in the prior year, the company earned $0.32 EPS. Hims & Hers Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.